The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Early use of BCMA-targeted therapies at first relapse in multiple myeloma
Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ and International Myeloma Foundation, Studio City, CA, discusses key treatment considerations for community oncologists managing patients with multiple myeloma at first relapse. He highlights the growing evidence supporting early use of BCMA-directed therapies, including CAR-T therapy, bispecific antibodies and antibody-drug conjugates (ADCs), rather than relying on traditional triplet regimens. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
